Speaker: Adam Hill
Adam Hill received his D.Phil. from Oxford University. For the ensuing 28 years he has been engaged in drug discovery with a focus on high throughput screening. After a post-doc at Harvard he established one of the first academic high throughput screening centers, at the University of Connecticut in 1995. After stints at Schering Plough and Millennium he spent 11 years at the Novartis Institutes for BioMedical Research where he headed the Screening group in Cambridge until 2016. Constantly innovating and improving on lead finding, Adam has aided in the discovery of a number of marketed therapeutics including Boceprevir (for HCV), Sonidegib (basal cell carcinoma), and LMI070 in the clinic for SMA.
He has also also been responsible for the development and implementation of a number of innovative approaches to drug discovery including the use of design of experiment, facilitated access to screening technologies, and the development of the MALDI PharmaPulse. An early adopter of modular automation, he has overseen the installation of a number of automation systems for sample management, assay development, small scale and large scale screening including BL2+ environments and bespoke solutions for cell culture and high content imaging.
Adam Hill is currently CEO of Prospective Research, Inc., an antibiotics discovery company based in Beverly, MA and a Partner in Triple Sharp Venture Engineering, an early stage life sciences VC.
In this webinar, Adam Hill discusses the changes and challenges in early drug discovery. Early drug discovery sets the foundation for the successful delivery of novel medicines to improve the quality of human life. The science for targeting new diseases has changed dramatically over the last five years, with more changes to come. The new challenges and limitations facing researchers in early drug discovery will be discussed in the context of the conventional technologies that exist, and where the need for disruptive technologies is most pressing.
Following this webinar, you will be able to:
- Recognize the complexity of the drug discovery process
- Explain why picking the right model is key to success
- Discuss new analytical methods
- List informatics challenges and methods
- Describe new and more efficient discovery strategies